Ya'll can stop searching Medline, 10k wizard and edgar now:
WILMINGTON, Del., Feb. 27 /PRNewswire/ -- AstraZeneca Pharmaceuticals, LP, (NYSE: AZN) has the best product pipeline in the pharmaceutical industry, according to a report in R&D Directions, a respected research and development publication.
In its annual review of the top pharmaceutical and biotechnology companies, R&D Directions ranked AstraZeneca's pipeline number one, and described it as "the richest" with "the strongest lineup of new products in
research and development."
"With five significant product launches expected in the next two years and a robust late stage pipeline supporting (six) therapeutic areas, AstraZeneca has the most exciting pipeline in the pharmaceutical industry ... In addition,
analysts are giving AstraZeneca's pipeline top marks, emphasizing its focus on diseases of particular medical importance," the report said.
"A superior pipeline is vital to our success as a company. To be recognized for having the best pipeline in the industry just two years after the merger that created AstraZeneca, is a tremendous tribute to the talent and
resources that have been invested into our research and development effort," said C.G. Johansson, President and CEO, AstraZeneca Pharmaceuticals LP, US.
AstraZeneca (NYSE: AZN) is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of $15.8 billion and leading positions in sales of gastrointestinal, oncology, anesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products. In the United States, AstraZeneca is an $8 billion healthcare business with more than 10,000 employees. |
